Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Debt / NOTE 0.599% 8/0
-
Market price (% of par)
-
98.37%
-
Total 13F principal
-
$420,418,350
-
Principal change
-
-$10,245,913
-
Total reported market value
-
$414,229,225
-
Number of holders
-
57
-
Value change
-
-$16,303,106
-
Number of buys
-
15
-
Number of sells
-
28
Institutional Holders of BIOMARIN PHARMACEUTICAL INC - NOTE 0.599% 8/0 as of Q2 2023
As of 30 Jun 2023 BIOMARIN PHARMACEUTICAL INC - NOTE 0.599% 8/0 had 57 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of $420,418,350 principal (par value or face value) of the bond of the company.
Largest 10 bondholders included BlackRock Inc., Voya Investment Management LLC, CITIGROUP INC, Calamos Advisors LLC, AVIVA PLC, ADVENT CAPITAL MANAGEMENT /DE/, SHENKMAN CAPITAL MANAGEMENT INC, Polar Capital Holdings Plc, Royal Bank of Canada, and PFM Health Sciences, LP.
This table shows 57 bond principal holders of the security as of 30 Jun 2023.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par) |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.